DexCom, Inc. (DXCM) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is...
DexCom, Inc. (DXCM) currently trades at a P/E ratio of 32.48 (historical range: 24.35–269.17, median: 82.27), placing it at the 8th percentile — cheap relative to its history, P/S ratio of 6.53 (range: 4.70–28.03, 17th percentile — cheap relative to its history), EV/EBITDA of 28.02 (range: 21.83–30.11, 52th percentile).
Over the historical period (2021-09-14 to 2026-10-16), DexCom, Inc.'s P/E ratio has contracted by 69% over the observed period (from an average of 152.6 to 47.7).
DexCom, Inc. trades below its historical valuation range, with most metrics below their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 32.48 | 82.27 | 8th | cheap relative to its history |
| P/S Ratio | 6.53 | 12.44 | 17th | cheap relative to its history |
| EV/EBITDA | 28.02 | 27.98 | 52th | near its historical average |
| FCF Yield | 4.33% | 1.14% | 91th | cheap relative to its history |
DexCom, Inc. (DXCM) Valuation & P/E History
DexCom, Inc. (DXCM) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry currently trading at $85.90 with a market capitalization of $32.4 billion. This page provides historical valuation analysis for DXCM based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 32.48 is below the historical median of 82.27, placing DXCM at the 8th percentile of its valuation range. The P/S ratio of 6.53 compares to a median of 12.44.
DXCM Valuation Metrics & Historical Range
The valuation table above shows DexCom, Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether DXCM is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests DXCM is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for DexCom, Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is DXCM Overvalued or Undervalued?
DexCom, Inc. trades below its historical valuation range, with most metrics below their median levels. The overall valuation percentile of 26 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive DXCM is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full DXCM analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.DXCM trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.